Synaptic proteins in neuron-derived extracellular vesicles as biomarkers for Alzheimer’s disease: novel methodology and clinical proof of concept

Abstract

Aims: Blood biomarkers can improve drug development for Alzheimer’s disease (AD) and its treatment. Neuron-derived extracellular vesicles (NDEVs) in plasma offer a minimally invasive platform for developing novel biomarkers that may be used to monitor the diverse pathogenic processes involved in AD. However, NDEVs comprise only a minor fraction of circulating extracellular vesicles (EVs). Most published studies have leveraged the L1 cell adhesion molecule (L1CAM) for NDEV immunocapture. We aimed to develop and optimize an alternative, highly specific immunoaffinity method to enrich blood NDEVs for biomarker development.

Methods: After screening multiple neuronal antigens, we achieved NDEV capture with high affinity and specificity using antibodies against Growth-Associated Protein (GAP) 43 and Neuroligin 3 (NLGN3). The EV identity of the captured material was confirmed by electron microscopy, western blotting, and proteomics. The specificity for neuronal origin was demonstrated by showing enrichment for neuronal markers (proteins, mRNA) and recovery of spiked neuronal EVs. We performed NDEV isolation retrospectively from plasma samples from two cohorts of early AD patients (N = 19 and N = 40) and controls (N = 20 and N = 19) and measured p181-Tau, amyloid-beta (Aβ) 42, brain-derived neurotrophic factor (BDNF), precursor brain-derived neurotrophic factor (proBDNF), glutamate receptor 2 (GluR2), postsynaptic density protein (PSD) 95, GAP43, and syntaxin-1.

Results: p181-Tau, Aβ42, and NRGN were elevated in AD samples, whereas proBDNF, GluR2, PSD95, GAP43, and Syntaxin-1 were reduced. Differences for p181-Tau, proBDNF, and GluR2 survived multiple-comparison correction and were correlated with cognitive scores. A model incorporating biomarkers correctly classified 94.7% of AD participants and 61.5% of control participants. The observed differences in NDEVs-associated biomarkers are consistent with previous findings.

Conclusion: NDEV isolation by GAP43 and NLGN3 immunocapture offers a robust novel platform for biomarker development in AD, suitable for large-scale validation.

Keywords

Biomarkers / exosomes / neuron-derived exosomes / Alzheimer’s disease

References

[1] Cummings J,Ritter A,Zhong K.Alzheimer’s disease drug development pipeline: 2019.Alzheimers Dement (N Y)2019;5:272-93 PMCID:PMC6617248

[2] van Dyck CH,Aisen P.Lecanemab in early Alzheimer’s disease.N Engl J Med2023;388:9-21

[3] DeTure MA.The neuropathological diagnosis of Alzheimer’s disease.Mol Neurodegener2019;14:32 PMCID:PMC6679484

[4] Rahimi J.Prevalence of mixed pathologies in the aging brain.Alzheimers Res Ther2014;6:82 PMCID:PMC4239398

[5] Hogan DB,Roberts JI.The Prevalence and incidence of dementia with lewy bodies: a systematic review.Can J Neurol Sci2016;43 Suppl 1:S83-95

[6] Jack CR Jr,Blennow K.ContributorsNIA-AA research framework: toward a biological definition of Alzheimer’s disease.Alzheimers Dement2018;14:535-62 PMCID:PMC5958625

[7] Hampel H,Molinuevo JL.Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.Nat Rev Neurol2018;14:639-52 PMCID:PMC6211654

[8] Croft PK,Godbole N,Salomon C.Ovarian-cancer-associated extracellular vesicles: microenvironmental regulation and potential clinical applications.Cells2021;10:2272 PMCID:PMC8471580

[9] Delgado-Peraza F,Volpert O.Neuronal and astrocytic extracellular vesicle biomarkers in blood reflect brain pathology in mouse models of Alzheimer’s disease.Cells2021;10:993 PMCID:PMC8146429

[10] Kapogiannis D,Shardell MD.Association of extracellular vesicle biomarkers with alzheimer disease in the baltimore longitudinal study of aging.JAMA Neurol2019;76:1340-51 PMCID:PMC6632160

[11] Wen SW,Lobb RJ.Breast cancer-derived exosomes reflect the cell-of-origin phenotype.Proteomics2019;19:e1800180

[12] Yanez-Mo M,Andreu Z.Biological properties of extracellular vesicles and their physiological functions.J Extracell Vesicles2015;4:27066

[13] Balusu S,De Rycke R.Identification of a novel mechanism of blood-brain communication during peripheral inflammation via choroid plexus-derived extracellular vesicles.EMBO Mol Med2016;8:1162-83 PMCID:PMC5048366

[14] Banks WA,Bullock KM,Ludwig N.Transport of extracellular vesicles across the blood-brain barrier: brain pharmacokinetics and effects of inflammation.Int J Mol Sci2020;21:4407 PMCID:PMC7352415

[15] Rufino-Ramos D,Mahjoum S.Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo.Biomaterials2022;281:121366 PMCID:PMC8886823

[16] Lachenal G,Chivet M.Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity.Mol Cell Neurosci2011;46:409-18

[17] Pfenninger KH,Helmke SM.Growth-regulated proteins and neuronal plasticity. A commentary.Mol Neurobiol1991;5:143-51

[18] Uchigashima M,Futai K.Neuroligin-3: A circuit-specific synapse organizer that shapes normal function and autism spectrum disorder-associated dysfunction.Front Mol Neurosci2021;14:749164 PMCID:PMC8526735

[19] Théry C,Aikawa E.Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.J Extracell Vesicles2018;7:1535750 PMCID:PMC6322352

[20] Sperling RA,Beckett LA.Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.Alzheimers Dement2011;7:280-92 PMCID:PMC3220946

[21] Shaw LM,Knapik-Czajka M.Alzheimer’s Disease Neuroimaging InitiativeCerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects.Ann Neurol2009;65:403-13 PMCID:PMC2696350

[22] Volpert EG,Kalia V.Novel modification of Luminex assay for characterization of extracellular vesicle populations in biofluids.BioRxiv2022;preprint:

[23] Khodashenas S,Forouzandeh Moghadam M.A cell ELISA based method for exosome detection in diagnostic and therapeutic applications.Biotechnol Lett2019;41:523-31

[24] Chan RB,Cortes EP.Comparative lipidomic analysis of mouse and human brain with Alzheimer disease.J Biol Chem2012;287:2678-88 PMCID:PMC3268426

[25] Soo CY,Zheng Y.Nanoparticle tracking analysis monitors microvesicle and exosome secretion from immune cells.Immunology2012;136:192-7 PMCID:PMC3403268

[26] Sódar BW,Pálóczi K.Low-density lipoprotein mimics blood plasma-derived exosomes and microvesicles during isolation and detection.Sci Rep2016;6:24316 PMCID:PMC4834552

[27] Sodero AO.24S-hydroxycholesterol: Cellular effects and variations in brain diseases.J Neurochem2021;157:899-918

[28] O'Brien K,Ughetto S,Breakefield XO.RNA delivery by extracellular vesicles in mammalian cells and its applications.Nat Rev Mol Cell Biol2020;21:585-606 PMCID:PMC7249041

[29] Fiandaca MS,Mapstone M.Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study.Alzheimers Dement2015;11:600-7.e1 PMCID:PMC4329112

[30] Mustapic M,Werner JK.Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes.Front Neurosci2017;11:278

[31] Chen Z,Kang JJ.Necroptotic astrocytes induced neuronal apoptosis partially through EVs-derived pro-BDNF.Brain Res Bull2021;177:73-80

[32] Jia L,Zhang H.Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid.Alzheimers Dement2019;15:1071-80

[33] Bhargava P,Kim S,Calabresi PA.Synaptic and complement markers in extracellular vesicles in multiple sclerosis.Mult Scler2021;27:509-18 PMCID:PMC7744427

[34] Goetzl EJ,Jicha GA,Schwartz JB.Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease.FASEB J2018;32:888-93 PMCID:PMC5888398

[35] Goetzl EJ,Schwartz JB.Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease.FASEB J2016;30:4141-8 PMCID:PMC5102122

[36] Hornung S,Bitan G.CNS-derived blood exosomes as a promising source of biomarkers: opportunities and challenges.Front Mol Neurosci2020;13:38 PMCID:PMC7096580

[37] Ludwig N,Reichert TE.Challenges in exosome isolation and analysis in health and disease.Int J Mol Sci2019;20:4684 PMCID:PMC6801453

[38] Huang G,Zhu Y,Jin D.Emerging technologies for profiling extracellular vesicle heterogeneity.Lab Chip2020;20:2423-37

[39] Vagner T,Mariscal J,Engman DM.Protein composition reflects extracellular vesicle heterogeneity.Proteomics2019;19:e1800167 PMCID:PMC7521840

[40] Valencia K.Exosomes in liquid biopsy: the nanometric world in the pursuit of precision oncology.Cancers (Basel)2021;13:2147 PMCID:PMC8124368

[41] Willms E,Mäger I,Vader P.Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression.Front Immunol2018;9:738 PMCID:PMC5936763

[42] Strittmatter SM,Fishman MC.GAP-43 as a plasticity protein in neuronal form and repair.J Neurobiol1992;23:507-20

[43] Zhang B,Wang W.Comparative proteomic analysis of the brain and colon in three rat models of irritable bowel syndrome.Proteome Sci2020;18:1 PMCID:PMC7041085

[44] Brennan K,FitzGerald SP.A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum.Sci Rep2020;10:1039 PMCID:PMC6978318

[45] Sun Y,Saito Y.Lipid profile characterization and lipoprotein comparison of extracellular vesicles from human plasma and serum.Metabolites2019;9:259 PMCID:PMC6918450

[46] Palviainen M,Varga Z.Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo-Implications for biomarker discovery.PLoS One2020;15:e0236439 PMCID:PMC7446890

[47] Zhou R,Zhang J.The decade of exosomal long RNA species: an emerging cancer antagonist.Mol Cancer2018;17:75 PMCID:PMC5861621

[48] FDA. Bioanalytical Method Validation: Guidance for Industry 2018. Available from: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf [Last accessed on 28 Mar 2023]

[49] Winston CN,Akers JC.Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile.Alzheimers Dement (Amst)2016;3:63-72 PMCID:PMC4925777

[50] Eren E,Shardell M.Extracellular vesicle biomarkers of Alzheimer’s disease associated with sub-clinical cognitive decline in late middle age.Alzheimers Dement2020;16:1293-304 PMCID:PMC7984100

[51] Lleó A,Alcolea D.Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid.Mol Cell Proteomics2019;18:546-60 PMCID:PMC6398205

[52] Korkut C,Koles K.Regulation of postsynaptic retrograde signaling by presynaptic exosome release.Neuron2013;77:1039-46 PMCID:PMC3626103

[53] Öhrfelt A,Dumurgier J.The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease.Alzheimers Res Ther2016;8:41 PMCID:PMC5048479

[54] Eren E,Troncoso J,Oh ES.Neuronal-derived EV biomarkers track cognitive decline in Alzheimer’s disease.Cells2022;11:436 PMCID:PMC8834433

[55] Haynes WA,Liu C.Empowering multi-cohort gene expression analysis to increase reproducibility.Pac Symp Biocomput2017;22:144-53 PMCID:PMC5167529

[56] Mattsson-Carlgren N,Blennow K.Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.Nat Commun2020;11:6252 PMCID:PMC7721731

[57] Bæk R,Varming K.The impact of various preanalytical treatments on the phenotype of small extracellular vesicles in blood analyzed by protein microarray.J Immunol Methods2016;438:11-20

[58] Binderup HG,Heegaard NHH,Andersen RF.Quantification of microRNA levels in plasma - Impact of preanalytical and analytical conditions.PLoS One2018;13:e0201069 PMCID:PMC6053236

[59] Jamaly S,Olsen R.Impact of preanalytical conditions on plasma concentration and size distribution of extracellular vesicles using Nanoparticle Tracking Analysis.Sci Rep2018;8:17216 PMCID:PMC6249294